Diagnostic and Therapeutic Biomarkers in Colorectal Cancer: a Review

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2022 Mar 9

PMID 35261794

Authors

Jessica Vieira de Assis

Lucelia Antunes Coutinho

Ifeoluwa Temitayo Oyeyemi

Oyetunde Timothy Oyeyemi

Rafaella Fortini E Queiroz Grenfell

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is a public health concern and the second most common type of cancer among men and women causing a significant mortality. Biomarkers closely linked to the disease morbidity could holds potential as diagnostic and/or prognostic biomarker for the disease. This review provides an overview of recent advances in the search for colorectal cancer biomarkers through genomics and proteomics according to clinical function and application. Specifically, a number of biomarkers were identified and discussed. Emphasis was placed on their clinical applications relative to the diagnosis and prognosis of CRC. The discovery of more sensitive and specific markers for CRC is an urgent need, and the study of molecular targets is extremely important in this process, as they will allow for a better understanding of colorectal carcinogenesis, identification and validation of potential genetic signatures.

Citing Articles

Overexpression of ZNF169 promotes the growth and proliferation of colorectal cancer cells via the upregulation of ANKZF1.

Zhang J, Wang Y, Hou S, Chi X, Ding D, Xue M Oncol Rep. 2024; 51(6).

PMID: 38666541 PMC: 11063753. DOI: 10.3892/or.2024.8741.

Identification and validation of a novel six-gene signature based on mucinous adenocarcinoma-related gene molecular typing in colorectal cancer.

Man Y, Xin D, Ji Y, Liu Y, Kou L, Jiang L Discov Oncol. 2024; 15(1):63.

PMID: 38443703 PMC: 10914658. DOI: 10.1007/s12672-024-00916-2.

Data mining identifies novel RNA-binding proteins involved in colon and rectal carcinomas.

Garcia-Cardenas J, Armendariz-Castillo I, Garcia-Cardenas N, Pesantez-Coronel D, Lopez-Cortes A, Indacochea A Front Cell Dev Biol. 2023; 11:1088057.

PMID: 37384253 PMC: 10293682. DOI: 10.3389/fcell.2023.1088057.

MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review.

Yang I, Yip K, Chang Y, Chen Y, Huang C, Tsai H Cancers (Basel). 2023; 15(5).

PMID: 36900159 PMC: 10000071. DOI: 10.3390/cancers15051358.

The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies.

Braumuller H, Mauerer B, Andris J, Berlin C, Wieder T, Kesselring R Cells. 2023; 12(1).

PMID: 36611932 PMC: 9818504. DOI: 10.3390/cells12010138.

References

Dupont C, Armant D, Brenner C . Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med. 2009; 27(5):351-7. PMC: 2791696. DOI: 10.1055/s-0029-1237423. View

Janowski M . Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 2009; 3(3):243-9. PMC: 2712802. DOI: 10.4161/cam.3.3.8260. View

Alves Martins B, de Bulhoes G, Cavalcanti I, Martins M, de Oliveira P, Martins A . Biomarkers in Colorectal Cancer: The Role of Translational Proteomics Research. Front Oncol. 2019; 9:1284. PMC: 6890575. DOI: 10.3389/fonc.2019.01284. View

Vacante M, Borzi A, Basile F, Biondi A . Biomarkers in colorectal cancer: Current clinical utility and future perspectives. World J Clin Cases. 2018; 6(15):869-881. PMC: 6288499. DOI: 10.12998/wjcc.v6.i15.869. View

Wang M, Li J, Huang J, Luo M . The Predictive Role of Mutation Status on Inhibitors in Breast Cancer Therapy: A Systematic Review and Meta-Analysis. Biomed Res Int. 2020; 2020:1598037. PMC: 7238354. DOI: 10.1155/2020/1598037. View

Li K, Qu S, Chen X, Wu Q, Shi M . Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int J Mol Sci. 2017; 18(2). PMC: 5343938. DOI: 10.3390/ijms18020404. View

Rapado-Gonzalez O, Majem B, Muinelo-Romay L, Alvarez-Castro A, Santamaria A, Gil-Moreno A . Human salivary microRNAs in Cancer. J Cancer. 2018; 9(4):638-649. PMC: 5858485. DOI: 10.7150/jca.21180. View

Villalba M, Evans S, Vidal-Vanaclocha F, Calvo A . Role of TGF-β in metastatic colon cancer: it is finally time for targeted therapy. Cell Tissue Res. 2017; 370(1):29-39. DOI: 10.1007/s00441-017-2633-9. View

Pan S, Wu Y, Cai S, Pan Y, Liu W, Bian L . Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression. Biochem Biophys Res Commun. 2015; 458(3):476-482. DOI: 10.1016/j.bbrc.2015.01.128. View

10.

Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y . Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA Metastatic Colorectal Cancers. Mol Ther. 2017; 25(5):1248-1258. PMC: 5417843. DOI: 10.1016/j.ymthe.2017.03.010. View

11.

Perissi V, Aggarwal A, Glass C, Rose D, Rosenfeld M . A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell. 2004; 116(4):511-26. DOI: 10.1016/s0092-8674(04)00133-3. View

12.

Zhang R, Xu G, Li Y, He L, Chen L, Wang G . The role of insulin-like growth factor 1 and its receptor in the formation and development of colorectal carcinoma. J Int Med Res. 2013; 41(4):1228-35. DOI: 10.1177/0300060513487631. View

13.

Zanatto R, Santos G, Oliveira J, Pracucho E, Nunes A, Lopes-Filho G . IMPACT OF KRAS MUTATIONS IN CLINICAL FEATURES IN COLORECTAL CANCER. Arq Bras Cir Dig. 2020; 33(3):e1524. PMC: 7743328. DOI: 10.1590/0102-672020200003e1524. View

14.

Venook A, Niedzwiecki D, Lenz H, Innocenti F, Fruth B, Meyerhardt J . Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017; 317(23):2392-2401. PMC: 5545896. DOI: 10.1001/jama.2017.7105. View

15.

Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W . Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Clin Cancer Res. 2006; 12(23):6985-8. DOI: 10.1158/1078-0432.CCR-06-1931. View

16.

Chalhoub N, Baker S . PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2008; 4:127-50. PMC: 2710138. DOI: 10.1146/annurev.pathol.4.110807.092311. View

17.

Kim J, Takeuchi H, Lam S, Turner R, Wang H, Kuo C . Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005; 23(12):2744-53. DOI: 10.1200/JCO.2005.07.078. View

18.

Vladoiu M, Labrie M, St-Pierre Y . Intracellular galectins in cancer cells: potential new targets for therapy (Review). Int J Oncol. 2014; 44(4):1001-14. DOI: 10.3892/ijo.2014.2267. View

19.

Kang S, Na Y, Joung S, Lee S, Oh S, Min B . The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. Medicine (Baltimore). 2018; 97(9):e0019. PMC: 5851768. DOI: 10.1097/MD.0000000000010019. View

20.

Subhash V, Ho B . Galectin 3 acts as an enhancer of survival responses in H. pylori-infected gastric cancer cells. Cell Biol Toxicol. 2016; 32(1):23-35. DOI: 10.1007/s10565-016-9315-3. View